The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...

The top-line results of the APOLLOE4 trial showed that valitramiprosate (ALZ-801) was unable to slow down cognitive decline ...

Alzheon's Alzheimer's drug showed nominal benefit in a subgroup of patients who suffer with mild cognitive impairment.

Dr. Gonzalo Hidalgo, a Neurologist at Reliant Specialty Infusions, said he believes his clinic is the first in Louisiana to treat patients using Kisunla.

Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), American ...

Valiltramiprosate was no better than placebo at slowing cognitive decline, as assessed by ADAS-Cog13, in the latest phase 3 ...

Wegovy and Zepbound are just the latest drug dyads to face-off in the competitive pharma market, continuing a legacy of ...

Some neurologists and a consumer watchdog worry that an Eli Lilly–affiliated direct-to-consumer telehealth platform for Alzheimer’s could lead to misdiagnosis or unnecessary treatment.

A consumer-driven weight loss market could put pharma at greater risk if a recession hits; the continued turmoil at FDA and other HHS agencies magnifies the uncertainty facing the industry; Lilly ...

Today's pharmaceutical stocks are facing the challenges of government-imposed drug price caps, waning demand for COVID-19 ...

Opinion: McDermott, Will & Emery's Byron Kalogerou and Meredith Cullen Schwartz say demand in the anti-obesity market and new ...